239 related articles for article (PubMed ID: 15844708)
1. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
Herrine SK; Brown RS; Bernstein DE; Ondovik MS; Lentz E; Te H
Dig Dis Sci; 2005 Apr; 50(4):719-26. PubMed ID: 15844708
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
3. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
5. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
[TBL] [Abstract][Full Text] [Related]
6. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.
Jensen DM; Marcellin P
Eur J Gastroenterol Hepatol; 2005 Sep; 17(9):899-904. PubMed ID: 16093865
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
Keating GM; Curran MP
Drugs; 2003; 63(7):701-30. PubMed ID: 12656650
[TBL] [Abstract][Full Text] [Related]
10. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.
Miyase S; Haraoka K; Ouchida Y; Morishita Y; Fujiyama S
J Gastroenterol; 2012 Sep; 47(9):1014-21. PubMed ID: 22382633
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.
Al-Ali J; Siddique I; Varghese R; Hasan F
Ann Hepatol; 2012; 11(2):186-93. PubMed ID: 22345335
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
[TBL] [Abstract][Full Text] [Related]
14. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Symonds WT; Hindes RG; Berrey MM
N Engl J Med; 2013 Jan; 368(1):34-44. PubMed ID: 23281974
[TBL] [Abstract][Full Text] [Related]
15. Telaprevir for retreatment of HCV infection.
Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
[TBL] [Abstract][Full Text] [Related]
16. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
Kumada H; Mochida S; Suzuki F; Chayama K; Karino Y; Nakamura K; Fujimoto G; Howe AY; Ludmerer SW; Mobashery N
J Gastroenterol Hepatol; 2016 Oct; 31(10):1674-1683. PubMed ID: 26936417
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
Méndez-Navarro J; Chirino RA; Corey KE; Gorospe EC; Zheng H; Morán S; Juarez JA; Chung RT; Dehesa-Violante M
Dig Dis Sci; 2010 Sep; 55(9):2629-35. PubMed ID: 19960257
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
